Augmentin 625mg (Amoxicillin+Clavulanate) Birmingham — Broad-Spectrum Antibiotic West Midlands UK 2026
PRODUCT NAME
Augmentin 625 mg Tablets (Amoxicillin 500 mg + Clavulanic Acid 125 mg) — Co-amoxiclav Antibiotic.
PRODUCT DETAILS
Augmentin 625 mg is a prescription beta-lactam antibacterial containing amoxicillin and clavulanic acid. Clavulanic acid inhibits certain beta-lactamase enzymes, helping protect amoxicillin from bacterial degradation.
PRODUCT SPECIFICATION
- Active Ingredients: Amoxicillin 500 mg + Clavulanic Acid 125 mg
- Strength: 625 mg total
- Dosage Form: Film-coated oral tablet
- Drug Class: Penicillin antibiotic + beta-lactamase inhibitor
- ATC Code: J01CR02
- Prescription Status: Prescription-only medicine in the UK
KEY FEATURES
- Combines amoxicillin with clavulanic acid
- Used for selected bacterial infections
- UK product information lists indications including adequately diagnosed bacterial sinusitis, acute otitis media, community-acquired pneumonia, certain urinary infections, skin/soft-tissue infections, dental infections with spreading cellulitis, and selected bone/joint infections.
- Should be used according to a healthcare professional's prescription and appropriate antimicrobial guidance.
INDUSTRY UPDATE — 2026
The current UK product information for Augmentin 625 mg was revised in February 2026. It emphasizes appropriate antibiotic selection based on the suspected pathogen, susceptibility, infection severity and site, while highlighting antimicrobial resistance considerations.
Important: Augmentin should not be presented as a treatment for viral infections, and antibiotic therapy should be used only when clinically appropriate. People with a history of serious penicillin or beta-lactam allergy should not take it without appropriate medical assessment.
Visit unnatipharmax.com | 📱 +91 82650 41513 | 📧 Unnatipharmax@gmail.com
FAQ 1: What role does Clavulanic Acid play in Augmentin 625mg — why is it added to Amoxicillin?
Clavulanic acid is a beta-lactamase inhibitor — it doesn't kill bacteria directly but protects Amoxicillin from destruction by bacterial enzymes. Many bacteria (particularly Staphylococcus aureus, Haemophilus influenzae, E. coli, Klebsiella, and Moraxella catarrhalis) produce beta-lactamase enzymes that break open the beta-lactam ring of penicillin-type antibiotics, rendering them ineffective. Clavulanic acid binds irreversibly to these beta-lactamase enzymes, acting as a "suicide inhibitor" that permanently inactivates the enzyme — allowing Amoxicillin to function normally against otherwise resistant organisms. The combination dramatically extends Augmentin's spectrum compared to Amoxicillin alone: covering beta-lactamase-producing Staphylococci (skin infections), Haemophilus (respiratory infections), and Gram-negative organisms (urinary tract infections). In Birmingham's GP practices, Augmentin 625mg is prescribed precisely when the infection pattern suggests beta-lactamase-producing organisms — bite wounds, skin and soft tissue infections after trauma, mixed-flora infections, and UTIs resistant to trimethoprim — where plain Amoxicillin would fail.
FAQ 2: Why does Augmentin 625mg cause more GI side effects than plain Amoxicillin, and how should Birmingham patients manage this?
Augmentin 625mg has significantly higher rates of gastrointestinal side effects than plain Amoxicillin — diarrhoea occurs in 9-10% of Augmentin users versus 3-5% with Amoxicillin; nausea and vomiting are also more frequent. The clavulanic acid component is the primary driver — it directly stimulates gastrointestinal motility through motilin-like receptor activation, causing accelerated intestinal transit and loose stools independent of its antibiotic effects. Augmentin also disrupts the normal gut microbiome more significantly than narrower-spectrum antibiotics, contributing to diarrhoea and occasional Clostridioides difficile-associated colitis risk. Management strategies for Birmingham patients: always take Augmentin 625mg with food (significantly reduces GI side effects); probiotics (Lactobacillus rhamnosus GG, Saccharomyces boulardii) taken simultaneously with antibiotic courses reduce antibiotic-associated diarrhoea by 40-60%; stay well hydrated; report severe or persistent diarrhoea, particularly if blood-stained or accompanied by fever — this requires assessment for C. difficile; and consider this GI profile when prescribing for patients with pre-existing IBS or inflammatory bowel disease where significant GI disturbance is particularly problematic.
FAQ 3: How does Augmentin 625mg treat dental infections in Birmingham's community — a major prescribing indication?
Dental infections — periapical abscesses, periodontal abscesses, and cellulitis from dental origin — are among the most common Augmentin 625mg prescribing indications in Birmingham's GP and dental practices. Dental infections typically involve mixed oral flora including anaerobes (Bacteroides, Fusobacterium, Peptostreptococcus) alongside aerobic Streptococci and Staphylococci. Amoxicillin alone covers the Streptococcal component well, but many oral anaerobes produce beta-lactamase — making Augmentin's clavulanate addition critical for effective anaerobic coverage. The standard Birmingham dental antibiotic protocol: Augmentin 625mg three times daily for 5-7 days alongside appropriate dental treatment (drainage of abscess, root canal initiation, or extraction). UK NICE and Faculty of General Dental Practice guidelines specifically recommend Amoxicillin-Clavulanate for dental infections where penicillin alone has failed or when significant tissue involvement (spreading cellulitis, trismus, dysphagia) indicates mixed-flora infection requiring broader coverage. Birmingham's dental community at the Birmingham Dental Hospital coordinates prescribing with microbiological guidance.
FAQ 4: What is the liver toxicity risk with Augmentin 625mg and how should Birmingham patients with liver disease be managed?
Augmentin (Amoxicillin-Clavulanate) is associated with drug-induced liver injury (DILI) — the most common antibiotic cause of DILI in the UK, accounting for approximately 1 in 5,000-12,000 treatment courses. The hepatotoxicity is primarily cholestatic (bile flow impairment) rather than hepatocellular, and the clavulanic acid component is the primary driver — not the Amoxicillin. Presentation: elevated bilirubin and alkaline phosphatase, jaundice, pruritus (itch), and fatigue, typically emerging 1-6 weeks after completing the course. For Birmingham patients with pre-existing liver disease: Augmentin should be used cautiously with monitoring if hepatic impairment is mild-moderate; severe hepatic impairment is a contraindication; prior DILI from Augmentin is an absolute contraindication to re-exposure. For elderly Birmingham patients — where cholestatic liver injury from Augmentin can be more severe — shorter courses and clinical monitoring are advisable. Birmingham's UHW hepatology team manages Augmentin DILI cases, which while uncommon require recognition by GPs who should report new jaundice appearing within weeks of Augmentin completion to the Yellow Card pharmacovigilance scheme.
FAQ 5: Is Augmentin 625mg appropriate for UTI treatment in Birmingham's elderly female population and what alternatives exist?
Urinary tract infections in Birmingham's elderly female population — a high-prevalence group requiring careful antibiotic selection — are addressed by Augmentin in specific circumstances. UK guidelines (NICE NG109) recommend trimethoprim or nitrofurantoin as first-line UTI antibiotics for most women, with Augmentin reserved for: UTIs resistant to first-line agents on culture and sensitivity; complicated UTIs with structural abnormality; pregnant women where nitrofurantoin is avoided near term; and patients with trimethoprim allergy or known trimethoprim-resistant E. coli from prior urine culture. Augmentin's broad spectrum is often unnecessary for simple UTIs where trimethoprim suffices — prescribing Augmentin empirically for uncomplicated UTIs contributes to antibiotic resistance selection pressure. Birmingham's primary care antimicrobial stewardship programme specifically discourages Augmentin for uncomplicated UTIs where first-line agents would be effective — but appropriately endorses it for complicated or resistant UTI situations where its broader coverage is clinically justified.
Website
Email Id
Contact Number
+91-8265041513
Augmentin-625-mg-Amoxicillin-Clavulanate-Birmingham
